Physician profile
David S Gloss
NPI 1821278912
$15,063.66
in general payments reported to CMS, 2019-2025
49 companies · $3,346 in 2025
The $3,346 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,527 · 2020: $109 · 2021: $227 · 2022: $2,104 · 2023: $2,799 · 2024: $3,952 · 2025: $3,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $60.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,036.66 |
| Education | $60.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $2,042.57 | 2019 | |
| Ucb, INC. | $1,201.49 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Abbvie INC. | $1,171.83 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $940.49 | 2022-2025 | Ingrezza, Ongentys |
| Cadwell Industries, INC | $790.00 | 2022 | |
| Biogen, INC. | $673.32 | 2022-2025 | Vumerity, Tysabri, Skyclarys |
| Pfizer INC. | $611.19 | 2023-2025 | |
| Mdd US Operations, LLC | $594.12 | 2023-2025 | Gocovri, Xadago, Apokyn |
| Sk Life Science, INC. | $583.42 | 2022-2025 | Xcopri |
| Argenx US, INC. | $533.46 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lundbeck LLC | $456.06 | 2023-2025 | Vyepti |
| Lilly USA, LLC | $417.41 | 2022-2025 | Amyvid, Emgality, Reyvow |
| Otsuka America Pharmaceutical, INC. | $399.05 | 2023-2025 | Rexulti, Nuedexta |
| Alexion Pharmaceuticals, INC. | $342.53 | 2022-2025 | Ultomiris |
| Neurelis, INC. | $321.31 | 2022-2025 | Valtoco |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $309.92 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Amgen INC. | $291.05 | 2022-2025 | Uplizna |
| Csl Behring | $270.48 | 2023-2025 | Hizentra |
| Grifols USA, LLC | $261.26 | 2023-2025 | Gamunex-C |
| Emd Serono, INC. | $195.46 | 2023-2025 | Mavenclad |
| Acorda Therapeutics, INC | $192.23 | 2023-2024 | Inbrija |
| Takeda Pharmaceuticals U.S.A., INC. | $188.64 | 2023-2025 | Gammagard, Hyqvia |
| Amneal Pharmaceuticals LLC | $185.44 | 2022-2024 | Rytary |
| Merz Pharmaceuticals, LLC | $184.98 | 2023-2025 | Xeomin, Ampyra, Inbrija |
| Teva Pharmaceuticals USA, INC. | $178.50 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ipsen Biopharmaceuticals, INC | $150.39 | 2023-2025 | Dysport |
| Eisai INC. | $143.61 | 2023-2025 | |
| Livanova USA, INC. | $141.69 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $140.10 | 2019 | |
| Greenwich Biosciences, INC. | $129.49 | 2019 | |
| Tg Therapeutics, INC. | $128.15 | 2023-2025 | |
| Kedrion Biopharma, INC. | $125.24 | 2024 | Koate, Kedrab, Gammaked |
| Ge Healthcare | $94.00 | 2025 | |
| Springworks Therapeutics, INC. | $87.09 | 2025 | Gomekli |
| Biohaven Pharmaceutical Holding Company Ltd. | $80.85 | 2022 | |
| Ani Pharmaceuticals, INC. | $78.29 | 2024-2025 | Purified Cortrophin Gel |
| Biocodex, INC. | $75.54 | 2024 | |
| Supernus Pharmaceuticals, INC. | $61.25 | 2019-2020 | |
| Genzyme Corporation | $53.90 | 2025 | |
| Celgene Corporation | $47.61 | 2022 | |
| Janssen Biotech, INC. | $37.29 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $30.69 | 2025 | |
| Revance Therapeutics, INC. | $21.90 | 2024 | Daxxify |
| Impel Pharmaceuticals INC. | $20.28 | 2023 | Trudhesa |
| Mallinckrodt Hospital Products INC. | $19.28 | 2023 | Acthar |
| Kyowa Kirin, INC. | $18.59 | 2022 | |
| Averitas Pharma INC. | $16.45 | 2023 | Qutenza |
| Axsome Therapeutics, INC. | $13.83 | 2025 | Symbravo |
| Insightec,INC | $11.94 | 2024 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gloss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.